James W. McBlane

1.3k total citations
19 papers, 969 citations indexed

About

James W. McBlane is a scholar working on Molecular Biology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, James W. McBlane has authored 19 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Physiology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in James W. McBlane's work include Biomedical Ethics and Regulation (10 papers), Pluripotent Stem Cells Research (7 papers) and CAR-T cell therapy research (6 papers). James W. McBlane is often cited by papers focused on Biomedical Ethics and Regulation (10 papers), Pluripotent Stem Cells Research (7 papers) and CAR-T cell therapy research (6 papers). James W. McBlane collaborates with scholars based in United Kingdom, United States and Netherlands. James W. McBlane's co-authors include Sheila L. Handley, Michaela Sharpe, Uri Ben‐David, Hugh Laverty, B. Kevin Park, Neil A. Hanley, Peter W. Andrews, Neil R. Kitteringham, Jens Reinhardt and Annamaria Rossi and has published in prestigious journals such as Cell stem cell, Psychopharmacology and European Journal of Cancer.

In The Last Decade

James W. McBlane

18 papers receiving 911 citations

Peers

James W. McBlane

CMN

Yingjie Wang China

Andrea L.O. Hebb Canada

Mahesh Kandasamy India

Nasim Vousooghi Iran

Eugene Wyatt United States

Margarita Arango-Lievano France

Yusuke Hatanaka Japan

Chang‐Lin Lu China

Martin Hadamitzky Germany

Galit Shaltiel Israel

Yingjie Wang China

James W. McBlane

418 ×1.0

CMN

440 ×1.1

80 ×0.4

323 ×1.7

86 ×0.5

Citations per year, relative to James W. McBlane James W. McBlane (= 1×) peers Yingjie Wang

Countries citing papers authored by James W. McBlane

Since Specialization

Citations

This map shows the geographic impact of James W. McBlane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. McBlane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. McBlane more than expected).

Fields of papers citing papers by James W. McBlane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. McBlane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. McBlane. The network helps show where James W. McBlane may publish in the future.

Co-authorship network of co-authors of James W. McBlane

This figure shows the co-authorship network connecting the top 25 collaborators of James W. McBlane. A scholar is included among the top collaborators of James W. McBlane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. McBlane. James W. McBlane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Ghazaly, Essam, Marija Sajic, Khadija Rantell, et al.. (2024). Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises. Current Issues in Molecular Biology. 46(8). 8209–8225. 3 indexed citations

Exley, Andrew & James W. McBlane. (2020). Regulating innovation in the early development of cell therapies. 1(1). 2 indexed citations

Exley, Andrew, Khadija Rantell, & James W. McBlane. (2020). Clinical development of cell therapies for cancer: The regulators' perspective. European Journal of Cancer. 138. 41–53. 6 indexed citations

Bando, Hideaki, Matteo Piazza, Genevíève Gowing, et al.. (2020). Safety of cell therapy products: in-vitro methods to assess the tumorigenicity of human cell-based therapeutic products. Cytotherapy. 22(5). S42–S42. 3 indexed citations

Sato, Yoji, Hideaki Bando, Matteo Piazza, et al.. (2019). Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy. 21(11). 1095–1111. 111 indexed citations

McBlane, James W.. (2019). Should cell- and gene-therapy developers engage with regulatory authorities?. Cell and Gene Therapy Insights. 5(7). 359–368. 1 indexed citations

McBlane, James W., et al.. (2018). Preclinical Development of Cell-Based Products: a European Regulatory Science Perspective. Pharmaceutical Research. 35(8). 165–165. 9 indexed citations

Chapman, Kathryn, Paul Baldrick, Antônio da Silva, et al.. (2016). Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. mAbs. 8(3). 427–435. 28 indexed citations

McBlane, James W.. (2015). Preclinical safety testing for cell-based products using animals. Biologicals. 43(5). 425–428. 5 indexed citations

10.

McBlane, James W.. (2015). Regulatory landscape for cell therapy – EU view. Biologicals. 43(5). 433–436. 3 indexed citations

11.

Jones, David, et al.. (2012). A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs). British Journal of Clinical Pharmacology. 76(2). 203–209. 6 indexed citations

12.

Goldring, Christopher E., Paul Duffy, Nissim Benvenisty, et al.. (2011). Assessing the Safety of Stem Cell Therapeutics. Cell stem cell. 9(2). 176–176. 7 indexed citations

13.

Goldring, Christopher E., Paul Duffy, Nissim Benvenisty, et al.. (2011). Assessing the Safety of Stem Cell Therapeutics. Cell stem cell. 8(6). 618–628. 175 indexed citations

14.

McCreary, Andrew C., et al.. (1997). 5-HT systems and anxiety: multiple mechanisms in the elevated X-maze.. PubMed. 48(1). 1–12. 13 indexed citations

15.

McBlane, James W. & Sheila L. Handley. (1994). Effects of two stressors on behaviour in the elevated X-maze: preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology. 116(2). 173–182. 65 indexed citations

16.

Handley, Sheila L. & James W. McBlane. (1993). 5HT drugs in animal models of anxiety. Psychopharmacology. 112(1). 13–20. 214 indexed citations

17.

Handley, Sheila L. & James W. McBlane. (1993). An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. Journal of Pharmacological and Toxicological Methods. 29(3). 129–138. 182 indexed citations

18.

Handley, Sheila L., et al.. (1993). Multiple serotonin mechanisms in animal models of anxiety. Behavioural Brain Research. 58(1-2). 203–210. 118 indexed citations

19.

Handley, Sheila L. & James W. McBlane. (1991). 5-HT-the disengaging transmitter?. Journal of Psychopharmacology. 5(4). 322–326. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact